Reply to 'hRap1B-retro: a novel human processed Rap1B gene blurs the picture?' by Zemojtel et al Leukemia (2006) We agree with the comments made by Zemojtel et al. 1 and we thank them very much for the proposed hypothesis. In our work published in the September issue of Leukemia, 2 we initially used previously published oligonucleotides 3 to analyze rap1b transcript in bone marrow samples from 27 patients with myelodysplastic syndromes (MDS) and two secondary acute myeloid leukemias (sAML). In one patient with RARS and abnormal The hRap1B-retro gene is localized on chromosome 5 q13.3. Upper part: summary of differences in the sequence alignment between hRap1B-retro and hRap1B cDNAs and the corresponding genomic regions on the 5th and 12th chromosomes. In addition to the three nucleotide substitutions in the open reading frame (ORF), seven more differences between both genes are present in the untranslated regions (UTRs). The coordinates above the sequences are relative to the start codon ATG in hRap1B cDNA (GI: 58219793). hRap1B-r_Ram1-3: full-length cDNAs of hRap1B-retro from Ramos cell line (GIs: 50475494, 50474682, 50470789); hRap1B-r_Neur: full-length cDNA of hRap1B-retro from neuroblastoma (GI: 50498405); hRap1B-r_Plac: full-length cDNA of hRap1B-retro from placenta (GI: 50492447). 5chr: genomic DNA sequence from chromosome 5 (GI: 51465008: 26064529-26060269), 12chr: genomic DNA sequence from chromosome 12 (GI: 29803948: 31147958-31197631). Lower part: exonic structure of the hRap1B-retro and hRap1B mother genes mapped onto their cDNAs. Numbering stands for exon numbers.
Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu) Letters to the Editor karyotype (45, XX, À7/46, XX (19/1)), we observed two substitutions as compared to rap1b cDNA published sequence, which we interpreted as two amino-acid substitutions in G12R and K42E in Rap1B protein. We then analyzed rap1b genomic DNA by using denaturating gradient gel electrophoresis. At that time, we were aware of the presence of a sequence highly homologous to rap1b corresponding to a pseudogene located on chromosome 5q13.3 and, in order to avoid the amplification of this pseudogene, we designed oligonucleotides located in the intronic sequences of rap1b on chromosome 12, including one pair specific for exon 2 and another one to amplify exon 3. Using this strategy, we did not identify any rap1b gene mutation in genomic DNA of 56 MDS patients tested. Unfortunately, DNA from the patient in whom we had identified substitutions in cDNA was not available for genomic analysis.
The rap1b pseudogene on chromosome 5q13.3 is a retrotransposon (hRap1B-retro) with two exons expected to lack intronic sequences. As indicated by Zemojtel and co-workers, an intronic sequence is actually created by insertion of a SVA sequence in the retrogene. Evidence for the transcription of this retrogene is provided by the fact that the corresponding cDNAs in the database are devoid of the intronic sequence. At the time we prepared our manuscript, we missed this information.
We would like to provide additional data that may reinforce the discussion on the role of rap1 gene products in leukemogenesis. We recently analyzed additional blast cell cDNAs from patients with sAML and de novo AML (n ¼ 8). In three of these samples, including two with normal karytotype and one with trisomy 8, we again identified the changes that could indicate amino-acid substitutions in G12R and K42E in Rap1B protein. In addition, we observed a third substitution suggesting a G77G mutation when compared to the published sequence of rap1b cDNA. Considering the similarity of nucleotide substitutions between the cDNAs that we have sequenced and the hRap1B-retro cDNA described by Zemojtel, we could have amplified hRap1B-retro cDNA encoded by the gene located on chromosome 5q13.3. However, we remain puzzled by the fact that the identified pattern of substitutions demonstrates a homozygous pattern. As using the same set of oligonucleotides unable to distinguish between rap1b and hrap1b-retro in the same PCR conditions, why did we detect the hrap1b-retro transcript in some cases whereas the rap1b transcript was amplified in the others? Because the set of oligonucleotides used for amplification of rap1b cDNA was also able to amplify hrap1b-retro transcript and genomic sequence, we first hypothesized that cDNA samples could be contaminated by genomic DNA. To test this hypothesis, we designed a genomic PCR that specifically amplified the hrap1b-retro gene as a 1350 bp fragment using a 5 0 oligonucleotide located in exon 1 and a 3 0 oligonucleotide located in the intronic region. The expected product was easily identified in the genomic DNA of controls and of the two sAML with amino-acid substitutions, but not in the corresponding cDNAs. These results confirmed that cDNA samples were not contaminated with genomic DNA. We could also hypothesize that we preferentially amplified the hrap1b-retro because of either a deletion of the mother gene or the amplification of the pseudogene locus. As mentioned previously, cytogenetic analysis (R-banding) of the reported patients did not show any abnormality of the 12q14 (rap1b) or the 5q13.3 (hrap1b-retro) regions. FISH analysis of these loci is ongoing in three of the four patients.
If the hrap1b-retro pseudogene is transcribed, the biological consequences may be equivalent to that of an activating mutation in the mother gene. Indeed, the G12R substitution involves an amino acid that is crucial for the regulation of the GTP loading of small G proteins of the Ras superfamily. Thus, there is a possibility that the corresponding protein is converted into an active state. During the course of our study, we tried to detect Rap1-GTP in bone marrow mononuclear cells from MDS patients using a RalGDS Ras-binding domain, as previously described. 4 Although a positive control was easily obtained after activation of normal platelets, we were unable to detect any activation of Rap1 in MDS cells.
In conclusion, it should be interesting to screen MDS patients for the expression of the hrap1b-retro transcript coupled to FISH analysis of the 12q14 and 5q13.3 loci. Evidence for a recurrent transcription of the pseudogene could lead to a novel therapeutic strategy targeting the anchorage of Rap1 to the plasma membrane by using geranylgeranyltransferase inhibitors. 5 Farnesyltransferase inhibitors of Ras have already been used in patients with high grade MDS, because of recurrent activating mutations of N-ras. However, sensitive tools for evaluating the efficacy of inhibitors on GTP loading of Ras and Rap1 are needed. 
